Genetic Variant in ACVR2B Is Associated with Lean Mass

Med Sci Sports Exerc. 2016 Jul;48(7):1270-5. doi: 10.1249/MSS.0000000000000889.

Abstract

Introduction: Low lean mass (LM) is a risk factor for chronic disease, a major cause of disability and diminished quality of life, and is a heritable trait. However, relatively few specific genetic factors have been identified as potentially influencing this trait.

Methods: In this study, we selected 1493 single-nucleotide polymorphisms (SNP) in 155 candidate genes involved in anabolic, catabolic, growth hormone, and other related pathways and examined their association with LM, assessed by dual-energy x-ray absorptiometry, in a sample of 2760 non-Hispanic and Hispanic white postmenopausal women from the Women's Health Initiative (WHI) Observational Study. We assessed the replication of our top findings in a meta-analysis of 20 genome-wide association studies (n = 38,292) conducted by the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium Musculoskeletal Working Group.

Results: We identified 32 SNPs that had nominally significant associations with LM in the WHI cohort. In the replication stage, we find that SNP rs2276541 in the activin A receptor, type IIB (ACVR2B), was significantly associated with LM (β = 0.15, P = 2.17 × 10). ACVR2B codes for a receptor for a negative regulator of skeletal muscle, myostatin, and has previously been identified in a candidate gene study as a determinant of skeletal muscle mass.

Conclusions: Our findings support a previously proposed role of ACVR2B allelic variation as a determinant of muscle mass and extend prior findings in men and women. Additional large-scale studies will be needed to confirm our findings in different populations.

Publication types

  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Activin Receptors, Type II / genetics*
  • Aged
  • Alleles
  • Body Composition / genetics*
  • Body Mass Index
  • Female
  • Genotype
  • Humans
  • Middle Aged
  • Muscle, Skeletal / physiology*
  • Phenotype
  • Polymorphism, Single Nucleotide*
  • Risk Factors

Substances

  • ACVR2B protein, human
  • Activin Receptors, Type II

Grants and funding